Treace Medical Concepts, Inc.

NASDAQ:TMCI

Medical - Devices

Healthcare
$4.53 +1.87%

+$0.08 today

Market cap
$296.98M
Beta
1.41
P/E (TTM)
-4.3
EPS (TTM)
-$0.95
52W Low $1.17High $7.78

Volume 0.18M

Average 0.73M

TMCI Income Before Tax

Profit after all operating and non-operating items but before income tax.

Treace Medical Concepts, Inc.NASDAQ: TMCI

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$17.96M, compared with -$15.92M a year earlier. Trailing-twelve-month income before tax was -$61.04M.

Context

  • Income before tax amounted to 27.7% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$17.96M or moves back toward the trailing-twelve-month quarterly average of -$15.26M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.96M-91.2% QoQ
Last fiscal yearDec 2025
-$59M-5.8% YoY
LTMMar 2026
-$61.04M-15.2% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.8%——
1 year-5.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(59M) USD
Year-over-year change
-5.8%

Income Before Tax vs competitors

How TMCI compares with its peers on the latest reported figures

  • TMCI's LTM Mar 2026 income before tax of -$61.04M is the 7th highest of the 8 companies compared; the peer median is -$43.64M.
  • Its year-over-year change of -15.2% is the 6th highest of 8, against a peer median of +19.8%.
  • Income before tax amounts to 29.4% of revenue for TMCI, versus a peer median of 16.3%.
TMCI Competitors Peer median
Income Before Tax for TMCI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BVSBioventus Inc.LTM Mar 2026$33.64M +167.9%—5.8%
KIDSOrthoPediatrics Corp.LTM Mar 2026-$39.58M +5.9%—16.3%
EOLSEvolus, Inc.LTM Mar 2026-$42.56M +23.3%—14.1%
TOIThe Oncology Institute, Inc.LTM Mar 2026-$43.64M +32.2%—8.0%
RXSTRxSight, Inc.LTM Mar 2026-$46.58M -75.9%—36.5%
CBLLCeriBell, Inc.LTM Mar 2026-$60.37M -35.7%—63.5%
TMCITreace Medical Concepts, Inc.LTM Mar 2026-$61.04M -15.2%—29.4%
LABStandard BioTools Inc.LTM Mar 2026-$87.83M +19.8%—101.8%
Peer median (excluding TMCI) -$43.64M+19.8%—16.3%

Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.42M141.84M187.12M209.36M212.69M
Cost of Revenue16.89M27.52M35.18M41.09M42.94M
Gross Profit77.53M114.32M151.94M168.26M169.75M
Gross Margin82.1%80.6%81.2%80.4%79.8%
Research & Development10.2M13.58M15.44M20.59M20.28M
Selling, General & Admin83.84M137.57M187.93M203.36M203.62M
Operating Expenses94.04M149.16M203.37M223.95M223.91M
Depreciation & Amortization685K2.13M5.35M8.42M10.5M
EBITDA(15.81M)(36.28M)(39.01M)(42.07M)(43.18M)
EBITDA Margin-16.7%-25.6%-20.8%-20.1%-20.3%
Operating Income(16.51M)(34.84M)(51.43M)(55.69M)(54.15M)
Operating Margin-17.5%-24.6%-27.5%-26.6%-25.5%
Interest Income18K1.31M6.73M4.88M2.78M
Interest Expense4.06M4.4M5.17M5.26M5.32M
Other Income / Expenses(4.04M)(7.97M)1.9M(55K)(4.85M)
Income Before Tax(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Pre-Tax Margin-21.8%-30.2%-26.5%-26.6%-27.7%
Income Tax Expense00000
Net Income(20.55M)(42.82M)(49.53M)(55.74M)(59M)
Net Margin-21.8%-30.2%-26.5%-26.6%-27.7%
EPS (Basic)(0.38)(0.77)(0.81)(0.90)(0.93)
EPS (Diluted)(0.38)(0.77)(0.81)(0.90)(0.93)
Weighted Avg Shares54.18M55.28M60.85M62.11M63.27M
Weighted Avg Shares (Diluted)54.18M55.28M60.85M62.11M63.27M

Treace Medical Concepts, Inc.

NASDAQ:TMCI

Intrinsic Alpha fair value

Locked

Current Price

$4.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.